You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
叮噹健康(09886.HK)公開發售獲超額認購7.2倍 發售價每股12港元
格隆匯 09-13 06:27

格隆匯9月13日丨叮噹健康(09886.HK)發佈公告,公司全球發售3353.7萬股股份,其中香港發售股份335.4萬股,國際發售股份3018.3萬股,另有15%超額配股權;發售價爲每股發售股份12.00港元,每手買賣單位500股;中金公司及招銀國際爲聯席保薦人;預期股份將於2022年9月14日於聯交所主板掛牌上市。

根據香港公開發售初步提呈發售的香港發售股份獲超額認購。公司合共接獲6502份有效申請,認購合共2415.55萬股香港發售股份,相當於香港公開發售初步可供認購香港發售股份總數約7.20倍。國際發售初步提呈發售的發售股份已獲超額認購,相當於國際發售初步可供認購發售股份總數約1.7倍(行使任何超額配股權前)。基於發售價每股12.00港元,根據基石投資協議,基石投資者已認購2484.65萬股發售股份。

按發售價每股12.00港元計算,公司估計自全球發售收取所得款項淨額約3.416億港元(假設超額配股權並無獲行使)。公司擬將該等所得款項淨額約45.0%用於業務擴張,例如進一步開發智慧藥房網絡,以及提升用戶增長及參與度;約15.0%用於優化技術系統及運營平臺;約10.0%用於提升服務及業務,例如建立全職醫生及藥師的專業架構;約20.0%用於潛在投資及收購或戰略合作,以及經營所在的醫療產業的價值鏈;及所得款項淨額約10.0%用於營運資金及其他一般公司用途。如超額配股權獲悉數行使,公司就因超額配股權獲行使而將予配發及發行的503.05萬股額外發售股份收取的額外所得款項淨額將約爲6040萬港元。倘超額配股權獲悉數行使,公司擬將額外所得款項淨額按上述比例作上述用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account